High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR

Table 1 Survival analysis and clinical response to EGFR-TKI treatment in relation to biomarkers of EGFR FISH and mutation in all patients

EGFR Status	PFS, months		p^#	OS, months		p^#	Tumor Response					p^*
EGFR Status	median	95%CI	p^#	median	95%CI	p^#	ORR (%)	Non-ORR (%)	p^*	DCR (%)	Non-DCR (%)	p^*
FISH + (n = 226)	11.2	8.9-13.5	< 0.001	30.2	23.8-36.5	< 0.001	84 (37.2)	142 (62.8)	< 0.001	192 (85.0)	34 (15.0)	< 0.001
FISH- (n = 276)	3.0	2.1-3.8	< 0.001	17.2	14.6-19.7	< 0.001	55 (19.9)	221 (80.1)	< 0.001	146 (52.9)	130 (47.1)	< 0.001
EGFR Mutation + (n = 252)	11.7	10.0-13.3	< 0.001	30.2	24.8-35.6	< 0.001	110 (43.7)	142 (56.3)	< 0.001	227 (90.1)	25 (9.9)	< 0.001
EGFR Mutation – (n = 247)	2.3	1.8-2.7	< 0.001	15.4	13.2-17.7	< 0.001	27 (10.9)	220 (89.1)	< 0.001	108 (43.7)	139 (56.3)	< 0.001
Mutation+/FISH + (n = 163)	12.9	10.0-15.9	0.075	35.9	27.4-44.3	0.051	72 (44.2)	91 (55.8)	0.821	149 (91.4)	14 (9.6)	0.339
Mutation+/FISH- (n = 89)	9.3	6.1-12.6	0.075	27.9	23.4-32.3	0.051	38 (42.7)	51 (57.3)	0.821	78 (87.6)	11 (12.4)	0.339
Mutation-/FISH + (n = 62)	4.4	2.3-6.4	< 0.001	25.0	14.1-35.9	0.009	11 (17.7)	51 (82.3)	0.047	42 (67.7)	20 (32.3)	< 0.001
Mutation-/FISH- (n = 185)	2.0	1.7-2.3	< 0.001	14.2	11.5-16.9	0.009	16 (8.6)	169 (91.4)	0.047	66 (35.7)	119 (64.3)	< 0.001

Abbreviation: FISH, Fluorescent in situ hybridization; ORR, Objective response rate; DCR, Disease control rate; PFS, Progression-free survival; OS, Overall survival.
^#p values (two-sided) calculated using the log-rank test.
^*p values (two-sided) calculated using Pearson’s chi-square test.

ISSN: 1479-5876